REPOSITORY ID,REPOSITORY LINK,SAMPLE NUMBER,STUDY TITLE,STUDY LINK,ASSAY TYPE,TECHNOLOGY,COUNTRY,DISEASE,DOID,STUDY DESIGN,BODY SITE,PLATFORM,PARTICIPANT FEATURES,AVERAGE SPOTLENGTH,RUN ID,Sample ID,Sample Name,COLLECTION DATE,LIBRARY LAYOUT,LAT LON,SAMPLE TYPE,ETHNICITY,ELO,URBANZATION,REGION,CITYVILLAGE,TARGET AMPLICON,DIET
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722374,SRS1527088,UG1138,10/21/2009,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722375,SRS1527091,UG1142,10/20/2009,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722376,SRS1527089,UG1194,11/03/2009,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722377,SRS1527090,UG1839,02/22/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722378,SRS1527092,UG1845,02/28/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722379,SRS1527093,UG1847,02/27/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722380,SRS1527094,UG1851,03/01/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722381,SRS1527095,UG1858,03/03/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722382,SRS1527096,UG1867,03/10/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722383,SRS1527097,UG1871,03/10/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722384,SRS1527098,UG1872,03/10/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722385,SRS1527099,UG1884,03/17/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722387,SRS1527100,UG1891,03/22/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722388,SRS1527101,UG1197,11/05/2009,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722389,SRS1527102,UG1896,03/23/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722390,SRS1527103,UG1900,03/24/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722391,SRS1527104,UG1908,03/28/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722392,SRS1527105,UG1917,03/31/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722393,SRS1527106,UG1930,04/12/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722394,SRS1527107,UG1935,04/14/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722395,SRS1527108,UG1937,04/14/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722396,SRS1527109,UG1942,04/20/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722397,SRS1527110,UG1944,04/21/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722398,SRS1527111,UG1945,04/20/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722399,SRS1527112,UG1200,11/04/2009,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722400,SRS1527113,UG1957,04/28/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722401,SRS1527114,UG1965,05/04/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722402,SRS1527115,UG1978,05/10/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722403,SRS1527116,UG1985,05/13/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722404,SRS1527117,UG1986,05/11/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722405,SRS1527118,UG1987,05/11/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722406,SRS1527120,UG1990,05/13/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722407,SRS1527119,UG2001,05/19/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722408,SRS1527121,UG2026,05/31/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722409,SRS1527123,UG2030,05/31/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722410,SRS1527122,UG1216,11/11/2009,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722411,SRS1527124,UG2032,06/02/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722412,SRS1527125,UG2044,06/08/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722413,SRS1527126,UG2090,06/29/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722414,SRS1527127,UG2100,07/05/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722415,SRS1527128,UG2102,07/05/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722416,SRS1527129,UG2103,07/06/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722417,SRS1527130,UG2105,07/05/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722418,SRS1527131,UG2123,07/13/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722419,SRS1527132,UG2134,07/19/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722420,SRS1527133,UG2135,07/19/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722421,SRS1527134,UG1222,11/17/2009,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722422,SRS1527136,UG2140,07/20/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722423,SRS1527135,UG2142,07/26/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722424,SRS1527137,UG2152,07/26/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722425,SRS1527138,UG2154,07/28/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722426,SRS1527139,UG2164,08/02/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722427,SRS1527140,UG2169,08/02/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722428,SRS1527141,UG2174,08/03/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722429,SRS1527142,UG2177,08/04/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722430,SRS1527143,UG2179,08/11/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722431,SRS1527144,UG2180,08/09/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722432,SRS1527145,UG1243,11/26/2009,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722433,SRS1527146,UG2188,08/10/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722434,SRS1527147,UG2192,08/11/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722435,SRS1527148,UG2194,08/16/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722436,SRS1527149,UG2195,08/16/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722437,SRS1527150,UG2205,08/19/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722438,SRS1527151,UG2206,08/18/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722439,SRS1527152,UG2208,08/23/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722440,SRS1527153,UG2212,08/23/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722441,SRS1527154,UG2216,08/24/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722442,SRS1527155,UG2239,09/07/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722443,SRS1527156,UG1254,12/03/2009,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722444,SRS1527157,UG2241,09/06/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722445,SRS1527158,UG2242,09/06/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722446,SRS1527159,UG2257,09/14/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722447,SRS1527160,UG2261,09/16/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722448,SRS1527162,UG2263,09/19/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722449,SRS1527161,UG2316,10/11/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722450,SRS1527163,UG2321,10/11/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722451,SRS1527164,UG2323,10/12/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722452,SRS1527165,UG2336,10/19/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722453,SRS1527166,UG2343,10/25/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722454,SRS1527167,UG1262,12/09/2009,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722455,SRS1527168,UG2352,10/26/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722456,SRS1527169,UG2357,10/27/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722457,SRS1527170,UG2361,11/01/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722458,SRS1527171,UG2378,11/08/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722459,SRS1527172,UG2403,11/23/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722460,SRS1527173,UG2405,11/22/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722461,SRS1527174,UG2413,11/24/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722462,SRS1527175,UG2432,12/01/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722463,SRS1527176,UG2442,12/06/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722464,SRS1527177,UG2444,12/06/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722465,SRS1527179,UG1266,12/10/2009,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722466,SRS1527178,UG2455,12/13/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722467,SRS1527180,UG2460,12/15/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722468,SRS1527181,UG1289,01/14/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722469,SRS1527182,UG1165,10/22/2009,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722470,SRS1527183,UG1290,01/14/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722471,SRS1527184,UG1292,01/14/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722472,SRS1527185,UG1325,02/08/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722473,SRS1527186,UG1328,02/08/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722474,SRS1527187,UG1341,02/15/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722475,SRS1527188,UG1342,02/18/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722476,SRS1527190,UG1360,03/04/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722477,SRS1527191,UG1363,03/04/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722478,SRS1527189,UG1390,03/22/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722479,SRS1527192,UG1396,03/25/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722480,SRS1527193,UG1166,10/20/2009,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722481,SRS1527194,UG1397,03/29/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722482,SRS1527195,UG1416,04/09/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722483,SRS1527196,UG1420,04/14/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722484,SRS1527197,UG1424,04/16/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722485,SRS1527198,UG1426,04/16/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722486,SRS1527199,UG1428,04/16/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722506,SRS1527200,UG1438,04/22/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722507,SRS1527201,UG1442,04/26/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722508,SRS1527202,UG1444,04/23/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722509,SRS1527203,UG1446,04/29/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722510,SRS1527204,UG1168,10/21/2009,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722511,SRS1527205,UG1454,05/05/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722512,SRS1527206,UG1473,05/17/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722513,SRS1527207,UG1477,05/18/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722514,SRS1527208,UG1483,05/26/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722515,SRS1527209,UG1488,05/27/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722516,SRS1527210,UG1492,05/27/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722517,SRS1527211,UG1497,06/07/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722518,SRS1527212,UG1499,06/07/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722519,SRS1527213,UG1500,06/08/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722520,SRS1527214,UG1549,07/14/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722521,SRS1527215,UG1169,10/21/2009,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722522,SRS1527216,UG1550,07/14/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722523,SRS1527217,UG1561,07/22/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722524,SRS1527218,UG1571,07/28/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722525,SRS1527219,UG1586,08/10/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722526,SRS1527220,UG1591,08/10/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722527,SRS1527221,UG1594,08/13/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722528,SRS1527222,UG1598,08/17/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722529,SRS1527223,UG1601,08/20/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722530,SRS1527224,UG1612,08/26/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722531,SRS1527225,UG1618,08/27/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722532,SRS1527226,UG1171,10/22/2009,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722533,SRS1527227,UG1623,08/31/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722546,SRS1527240,UG1625,09/02/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722547,SRS1527241,UG1628,09/02/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722548,SRS1527242,UG1630,09/03/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722549,SRS1527243,UG1634,09/06/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722550,SRS1527244,UG1651,09/16/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722551,SRS1527245,UG1652,09/17/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722552,SRS1527246,UG1665,09/28/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722553,SRS1527247,UG1674,10/07/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722554,SRS1527248,UG1689,10/19/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722555,SRS1527249,UG1175,10/26/2009,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722556,SRS1527250,UG1690,10/21/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722557,SRS1527251,UG1696,10/21/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722558,SRS1527252,UG1705,10/28/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722559,SRS1527253,UG1711,11/03/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722560,SRS1527255,UG1712,11/02/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722561,SRS1527256,UG1714,11/04/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722562,SRS1527254,UG1717,11/04/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722563,SRS1527257,UG1720,11/08/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722564,SRS1527258,UG1728,11/18/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722565,SRS1527259,UG1747,12/02/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722580,SRS1527274,UG1176,10/28/2009,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722581,SRS1527275,UG1753,12/15/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722582,SRS1527276,UG1759,12/20/2010,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722583,SRS1527277,UG1765,01/05/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722584,SRS1527278,UG1773,01/11/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722585,SRS1527279,UG1774,01/12/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722586,SRS1527280,UG1776,01/14/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722587,SRS1527281,UG1777,01/14/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722588,SRS1527282,UG1779,01/18/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722589,SRS1527283,UG1784,01/20/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722590,SRS1527284,UG1790,01/25/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722591,SRS1527285,UG1186,10/29/2009,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722593,SRS1527286,UG1792,01/25/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722594,SRS1527287,UG1794,01/27/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722595,SRS1527288,UG1795,01/27/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722596,SRS1527289,UG1798,02/02/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722597,SRS1527290,UG1799,02/02/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722598,SRS1527291,UG1803,02/07/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722599,SRS1527292,UG1804,02/07/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722600,SRS1527293,UG1813,02/10/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722601,SRS1527294,UG1816,02/10/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
PRJNA305936,PRJNA305936,182.0,Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia,27447987,Amplicon,Illumina,Uganda,"Tuberculosis,HIV","399, 526",Case-control,Lung,Illumina Miseq, ,502.0,SRR3722602,SRS1527295,UG1827,02/17/2011,Paired,"0.347596, 32.582520",Bronchoalveolar lavage,,,Urban,,Kampala,v4,
